News

Filter

Current filters:

AranespBiotechnology

1 to 9 of 14 results

Amgen to pay $24.9 million to resolve false claims on Aranesp marketing

17-04-2013

USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech company, has agreed to pay the…

AmgenAranespBiotechnologyFinancialLegalNorth America

Amgen's Aranesp fails in heart patients; to invest $200 million in Singapore

18-01-2013

USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech firm, announced top-line results…

AmgenAranespAsia-PacificBiotechnologyCardio-vascularProductionResearch

News briefs: Celgene deal with Sutro; Amgen pleads guilty to misbranding

19-12-2012

US biotech firm Celgene Corp (Nasdaq: CELG) has entered a collaboration with San Francisco-based Sutra…

AmgenAranespBiotechnologyCelgeneFinancialLegalLicensingNorth AmericaSutro Biopharma

US FDA modifies dosing for ESA’s Aranesp, Epogen and Procrit on cardiovascular risks

27-06-2011

The US Food and Drug Administration on Friday recommended more conservative dosing guidelines for erythropoiesis-stimulating…

AmgenAranespBiotechnologyEpogenJohnson & JohnsonNorth AmericaOncologyPharmaceuticalProcritRegulation

New guideline from ASH and ASCO recommends caution regarding ESA use in cancer patients

28-10-2010

An updated joint guideline by the American Society of Hematology (ASH) and the American Society of Clinical…

AmgenAranespBiotechnologyEpogenImmunologicalsJohnson & JohnsonOncologyPharmaceuticalProcritRegulation

1 to 9 of 14 results

COMPANY SPOTLIGHT

Menarini

Back to top